Home | Structured Search | Drug Resource
Find: within
Obesity > Hospitalization Author: George A. Bray, MD
Editorial changes - 2009-11-18
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Quality Measures Quality Measures

Rationale:

  • Complications of obesity need intensive inpatient care.

Evidence:

  • In a large controlled study (277), a large review (339), and a meta-analysis (340), several procedures are available to bariatric surgeons.
  • Gastric-bypass surgery produces more weight loss that appears to be maintained more successfully than gastroplasty or laparoscopic gastric bands (277; 341; 342).
  • In a systematic review and meta-analysis, 78.1% of patients with diabetes had a remission after bariatric surgery (343); bilio-pancreatic diversion was more effective than gastric bypass, which was in turn better than banding (343).
  • Bariatric surgery may be a cost-effective treatment in patients recently diagnosed with type 2 diabetes (344; 345).
  • Bariatric surgical procedures including gastric bypass can be done by laparoscopic surgery (346).
  • A gastric sleeve produced more weight loss after 1 and 3 years than did adjustable gastric banding (347).
  • Venous thrombolism is a risk of bariatric surgery (348).
  • Complications including anatomic leaks, inadequate reduction in gastric size, or inadequate weight loss may require repeated hospitalization and surgery with similar risk (339; 349).
  • Gastric operations for obesity reduce mortality (350; 351), increase longevity (352), and improve quality of life (352; 353).
  • Malabsorptive bariatric surgery corrects both insulin hypersecretion and insulin resistance at a time when BMI is still high (354).
  • Omentectomy added no benefit to gastric bypass in one study (355).

Comments:

  • Complications of deep venous thromboembolism can be reduced by treatment with low-dose dalteparin (356).

FAQs
George A. Bray, MD, is a speaker for Eli Lilly, Amylin Corp., and Merck & Co., received grants from Merck & Co., and Takeda Pharmaceuticals; and has consulted for Sanofi-Aventis, Merck, and Amylin.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.